In vitro evaluation of 225 Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme

2018 ◽  
Vol 92 (1) ◽  
pp. 1344-1356 ◽  
Author(s):  
Agnieszka Majkowska-Pilip ◽  
Maria Rius ◽  
Frank Bruchertseifer ◽  
Christos Apostolidis ◽  
Mirjam Weis ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Substance P ◽  
Targeted Alpha Therapy ◽  
In Vitro Evaluation ◽  
Alpha Therapy

scholarly journals Recurrent glioblastoma multiforme – targeted alpha therapy with 213Bi-DOTA-Substance P

2016 ◽  
Vol 118 ◽  
pp. S16 ◽  
Author(s):  
L. Krolicki ◽  
B. Królicki ◽  
A. Morgenstern ◽  
J. Kunikowska ◽  
H. Koziara ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Substance P ◽  
Recurrent Glioblastoma ◽  
Recurrent Glioblastoma Multiforme ◽  
Targeted Alpha Therapy ◽  
Alpha Therapy

scholarly journals Systemic Targeted Alpha Radiotherapy for Cancer - A Review

2014 ◽  
Vol 6 (1) ◽  
pp. 21-38 ◽  
Author(s):  
Barry J Allen
Keyword(s):  
Glioblastoma Multiforme ◽  
Cancer Cells ◽  
Medical Physics ◽  
Metastatic Cancer ◽  
External Beam Radiotherapy ◽  
Palliative Therapy ◽  
Experimental Therapy ◽  
Alpha Radiation ◽  
Targeted Alpha Therapy ◽  
Alpha Therapy

The fundamental principles of internal targeted alpha therapy for cancer were established many decades ago. The high linear energy transfer (LET) of alpha radiation to the targeted cancer cells causes double strand breaks in DNA. At the same time, the short range of alpha- radiation spares adjacent normal tissues. This targeted approach complements conventional external beam radiotherapy and chemotherapy. Such therapies fail on several fronts, such as lack of control of some primary cancers (eg glioblastoma multiforme) and inhibition of the development of lethal metastatic cancer after successful treatment of the primary cancer. This review charts the developing role of systemic high LET in internal radiation therapy. Targeted alpha therapy is a rapidly advancing experimental therapy that holds promise to deliver high cytotoxicity to targeted cancer cells. Initially thought to be indicated for leukaemia and micrometastases, there is now evidence that solid tumours can also be regressed. Alpha therapy may be molecular or physiological in its targeting. Alpha emitting radioisotopes such as Bi-212, Bi-213, At-211 and Ac-225 are used to label monoclonal antibodies or proteins that target specific cancer cells. Alternatively, radium-233 is used for palliative therapy of breast and prostate cancers because of its bone seeking properties. In this review, preclinical studies and clinical trials of alpha therapy are discussed for leukaemia, lymphoma, melanoma, glioblastoma multiforme, bone metastases, ovarian cancer, pancreatic cancer and other cancers.   DOI: http://dx.doi.org/10.3329/bjmp.v6i1.19755 Bangladesh Journal of Medical Physics Vol.6 No.1 2013 21-38

scholarly journals Pharmacological in vitro evaluation of new substance P–cyclodextrin derivatives designed to drug targeting towards NK1-receptor bearing cells

2001 ◽  
Vol 1541 (3) ◽  
pp. 150-160 ◽  
Author(s):  
Christophe Péan ◽  
Anne Wijkhuisen ◽  
Florence Djedaïni-Pilard ◽  
Jacqueline Fischer ◽  
Stéphane Doly ◽  
...  
Keyword(s):  
Substance P ◽  
Drug Targeting ◽  
Nk1 Receptor ◽  
Cyclodextrin Derivatives ◽  
In Vitro Evaluation

scholarly journals In vitro evaluation of substance-P conjugated nanofibers for potential wound dressing material

2016 ◽  
Vol 4 ◽  
Author(s):  
Kim Min Sup ◽  
Park Sang Jun ◽  
Gu Bon Kang ◽  
Khang Gilson ◽  
Kim Chun Ho
Keyword(s):  
Substance P ◽  
Wound Dressing ◽  
In Vitro Evaluation

scholarly journals A Novel Single-Step-Labeled 212Pb-CaCO3 Microparticle for Internal Alpha Therapy: Preparation, Stability, and Preclinical Data from Mice

Materials ◽  
2021 ◽  
Vol 14 (23) ◽  
pp. 7130
Author(s):  
Ruth Gong Li ◽  
Kim Lindland ◽  
Tina Bjørnlund Bønsdorff ◽  
Sara Westrøm ◽  
Roy Hartvig Larsen
Keyword(s):  
Cytotoxic Effect ◽  
Single Step ◽  
Stability Assessment ◽  
Promising Candidate ◽  
Targeted Alpha Therapy ◽  
Suitable Material ◽  
In Vitro Stability ◽  
Alpha Therapy ◽  
Carrier Vehicle

Lead-212 is recognized as a promising radionuclide for targeted alpha therapy for tumors. Many studies of 212Pb-labeling of various biomolecules through bifunctional chelators have been conducted. Another approach to exploiting the cytotoxic effect is coupling the radionuclide to a microparticle acting as a carrier vehicle, which could be used for treating disseminated cancers in body cavities. Calcium carbonate may represent a suitable material, as it is biocompatible, biodegradable, and easy to synthesize. In this work, we explored 212Pb-labeling of various CaCO3 microparticles and developed a protocol that can be straightforwardly implemented by clinicians. Vaterite microparticles stabilized by pamidronate were effective as 212Pb carriers; labeling yields of ≥98% were achieved, and 212Pb was strongly retained by the particles in an in vitro stability assessment. Moreover, the amounts of 212Pb reaching the kidneys, liver, spleen, and skeleton of mice following intraperitoneal (i.p.) administration were very low compared to i.p. injection of unbound 212Pb2+, indicating that CaCO3-bound 212Pb exhibited stability when administered intraperitoneally. Therapeutic efficacy was observed in a model of i.p. ovarian cancer for all the tested doses, ranging from 63 to 430 kBq per mouse. Lead-212-labeled CaCO3 microparticles represent a promising candidate for treating intracavitary cancers.

Targeted alpha therapy of recurrent glia tumors: clinical experience with 225 Ac-Substance-P

2020 ◽  
Author(s):  
F Bruchertseifer ◽  
L Krolicki ◽  
J Kunikowska ◽  
H Koziara ◽  
B Krolicki ◽  
...  
Keyword(s):  
Substance P ◽  
Clinical Experience ◽  
Targeted Alpha Therapy ◽  
Alpha Therapy

Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma

2018 ◽  
Vol 46 (3) ◽  
pp. 614-622 ◽  
Author(s):  
Leszek Królicki ◽  
Frank Bruchertseifer ◽  
Jolanta Kunikowska ◽  
Henryk Koziara ◽  
Bartosz Królicki ◽  
...  
Keyword(s):  
Substance P ◽  
Recurrent Glioblastoma ◽  
Targeted Alpha Therapy ◽  
Safety And Efficacy ◽  
Alpha Therapy
Sign in / Sign up

Export Citation Format

Share Document